

Attorney Docket No.: 54704.8036.US03 (UMD-0072)
Inventors: John Langenfeld
Serial No.: 10/692,824
Filing Date: October 23, 2003
Page 15

The following listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

Claim 1 (currently amended): A method of reducing vascularization of a bone morphogenetic protein-2 overexpressing tumor in a subject comprising administering to a subject having a tumor that overexpresses bone morphogenetic protein-2 (BMP-2) a therapeutically effective amount of a bone morphogenetic protein-2 (BMP-2) activity inhibitor thereby reducing vascularization of a BMP-2 overexpressing tumor in the subject, wherein said BMP-2 activity inhibitor comprises noggin.

Claims 2-13 (canceled).

Claim 14 (original): The method of claim 1, wherein the BMP-2 activity inhibitor is administered in a pharmaceutically acceptable carrier.

Claim 15 (canceled).

Claim 16 (currently amended): A method of reducing vascularization of a bone morphogenetic protein-2 overexpressing tumor in a subject comprising administering to a subject having a tumor that overexpresses bone morphogenetic protein-2 (BMP-2) a therapeutically effective amount of an expression vector having a

Attorney Docket No.: 54704.8036.US03 (UMD-0072)
Inventors: John Langenfeld
Serial No.: 10/692,824
Filing Date: October 23, 2003
Page 16

nucleic acid sequence encoding a BMP-2 activity inhibitor and a selective promoter that is operably linked to the nucleic acid sequence thereby reducing vascularization of a BMP-2 overexpressing tumor in the subject, wherein said BMP-2 activity inhibitor comprises noggin,

Claim 17 (canceled).

Claim 18 (original): The method of claim 16, wherein the expression vector is administered in a pharmaceutically acceptable carrier.

Claims 19-20 (canceled).